Eli Lilly Gains 4.6% as Goldman Sachs Lifts Price Target to $1,413
Key TakeawaysEli Lilly shares rose 4. 6% today to a record high after Goldman Sachs raised its price target to $1,413 from $1,371 and kept its Buy rating.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
